You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of SP-A Derived Peptidomimetics for the Treatment of Asthma- Phase II

    SBC: RaeSedo, LLC            Topic: NHLBI

    Current treatments for asthma, while reducing exacerbations in a subset of patients by focusing on airway inflammation, do not eliminate them. Asthma exacerbations are a significant cause of morbidity and mortality in asthma as they can lead to airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and lost productivi ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Critical angle reflection imaging for label-free quantification of molecular interactions

    SBC: BIOSENSING INSTRUMENT INC            Topic: 400

    TITLE: Critical angle reflection imaging (CARi) for label-free quantification of molecular interactions SUMMARYMeasuring molecular interactions of proteins are critical for understanding protein functions and cellular processes, for discovery and validating biomarkers, and for developing and screening drugs. In particular, membrane proteins play key roles in many cellular functions and are the lar ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  3. eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis

    SBC: AQUALUNG THERAPEUTICS, CORP            Topic: NHLBI

    ABSTRACT The development of radiation-induced lung injury (RILI) is a potentially fatal toxicity in cancer patients undergoing thoracic radiotherapy or in individuals exposed to ionizing radiation (IR) from a nuclear incident. The pathobiology of radiation pneumonitis and radiation-induced lung fibrosis (RILF) is complex but includes the deleterious effects of unchecked inflammation (reactive oxyg ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma

    SBC: Faknostics, LLC            Topic: 102

    Abstract Melanoma is the deadliest form of skin cancer, affecting an estimated 1.2 million Americans. The disease has a high propensity for dissemination, and metastatic melanoma has a dismal prognosis, with a median survival of only 5–8 months. Healthcare costs for melanoma in 2021 are projected to reach nearly $4 billion, with a rising incidence rate. Despite considerable efforts in recent yea ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Clinical Text Automatic De-Identification to Support Large Scale Data Reuse and Sharing

    SBC: Clinacuity, Inc            Topic: 400

    The adoption of Electronic Health Record (EHR) systems is growing at a fast pace in the U.S., and this growth results in very large quantities of patient clinical data becoming available in electronic format with tremendous potential but an equally large concern for patient confidentiality breaches. Secondary use of clinical data is essential to fulfill the potential for high quality healthcare, i ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI)

    SBC: AQUALUNG THERAPEUTICS, CORP            Topic: NHLBI

    Mortality rates in intensive care units (ICUs) are unacceptably high and are directly related to the duration of mechanical ventilation that is required to support patients with respiratory failure. For example, acute respiratory distress syndrome (ARDS) is a vexing acute inflammatory lung disease requiring mechanical ventilatory support as the result of severe hypoxemia and respiratory failure. T ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Single application thixotropic antibiotic delivery systems for otitis externa

    SBC: Promiliad Biopharma Incorporated            Topic: NIDCD

    PROJECT SUMMARY Outer ear infections (otitis externa or OE) affect an estimated 10% of people in their lifetime, with associated healthcare costs amounting to over $500 million annually. The pathology is mostly treatable in the general population with topical antibiotics regimes, and can be supplemented in severe cases with systemic counterparts. However, incorrect application or non-compliance wi ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Production and Characterization of Human Immunoglobulin Producing Goats for Diagnostic Reagents and Therapeutics

    SBC: SAB CAPRA, LLC            Topic: NIAID

    Project Summary/Abstract The ultimate goal of this phase II STTR proposal is to expand the capabilities of SABandapos;s diversitAb™ platform by continuing advanced development of Transchromosomic goats (TcGs). This will be accomplished by producing male and female goat endogenous immunoglobulin gene knockout cell lines that contain SAB Capraandapos;s human artificial chromosome (HAC) which encod ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Novel antibacterial agents derived from natural products

    SBC: Promiliad Biopharma Incorporated            Topic: NIAID

    SPECIFIC AIMSAntibiotic resistance among common bacterial pathogens is a serious public health problem as it compromises our ability to treat infectious disease. The resistance problem is compounded by the relative lack of discovery of new antibiotics, especially those with novel mechanisms of action. New antibiotics are critically needed as resistance to recently developed antibiotics is growing. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Application of PPODA-QT for embolization of aneurysms

    SBC: ANEUVAS TECHNOLOGIES INC            Topic: 101

    PROJECT SUMMARY/ABSTRACTA cerebral aneurysm is an abnormal enlargement or pouch that forms from a weakened vessel segment in the brain. Often going unnoticed and untreated, an aneurysm can cause a sudden and catastrophic hemorrhage or stroke. Approximately 15 % of patients die from an aneurysm rupture even before receiving medical attention and 25 % of patients die despite medical treatment. Patie ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government